GlobalData shows lucrative biosimilars space

The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking the overall biologics market value from $162 billion in 2013 to more than $262 billion by 2019, says research and consulting firm GlobalData.







The company’s latest report states that patent expirations of branded biologics and the introduction of clearer regulatory frameworks for biosimilars after 2019 will see the latter capturing the market share from biologics.

Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says: “There are a number of factors driving the initiative towards the global adoption of biosimilars, from austerity measures and slow economic growth in the US, to an aging population and increasing demand for healthcare in countries such as Japan.

Indian chemical industry - Growth

The Indian chemical industry was the second largest producer in Asia in terms of volume, after China. The Indian chemical industry is currently at US $136 Billion approximately, and is likely to grow at a compound annual growth rate of 10-12 percent over the next five years. 

Over the last decade, the Indian chemical industry has strengthened its competitiveness in agrochemicals and pharmaceuticals segments, becoming one of the major exporters for these segments, globally. The industry also witnessed increased investments in the specialty sector, which is poised to be the fastest growing segment in India.

The challenges and opportunities in the chemicals and materials space in context to the global chemicals and materials industry. The event will also seek to provide an understanding of the mega trends, technology and innovation impacting the industry, and the role of various stakeholders for leveraging these opportunities.